Welcome to our dedicated page for Forbion European Acquisition SEC filings (Ticker: engnw), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Forbion European Acquisition's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Forbion European Acquisition's regulatory disclosures and financial reporting.
enGene Holdings Inc. entered a new sales agreement with Leerink Partners that allows it to sell common shares from time to time in an at-the-market offering for an aggregate offering price of up to $100,000,000 under its existing shelf registration.
Leerink Partners will act as sales agent and receive a commission of up to 3.0% of the gross proceeds, with no obligation for enGene to sell or for Leerink to place any shares. In connection with this new arrangement, enGene terminated its prior open market sale agreement with Jefferies LLC, under which no common shares had been sold.
enGene Holdings Inc. reported a larger quarterly net loss as it continues to invest heavily in its lead bladder cancer gene therapy, detalimogene. For the three months ended January 31, 2026, net loss was
To support development and potential commercialization, enGene significantly strengthened its balance sheet. Cash, cash equivalents and marketable securities rose to
enGene Holdings Inc. reported a first quarter 2026 net loss attributable to common shareholders of approximately $29.8 million, or $0.44 per share, compared with about $24.6 million, or $0.48 per share, a year earlier. Operating expenses rose to $31.2 million from $26.6 million, driven by higher research and development spending on the LEGEND trial and preparation for a planned Biologics License Application, as well as increased general and administrative costs to support public company operations. Cash, cash equivalents and marketable securities were $312.5 million as of January 31, 2026, supported by a $140.1 million underwritten offering completed in November 2025 and an expanded $125 million debt facility with Hercules Capital, giving an expected cash runway into the second half of 2028. Preliminary data from the LEGEND pivotal cohort in high-risk, BCG-unresponsive non-muscle invasive bladder cancer showed complete response rates of 63% at any time (n=62), 56% at 3 months (n=62), and 62% at 6 months (n=37), with a generally favorable tolerability profile and low rates of treatment-related dose interruptions and discontinuations.
enGene Holdings Inc. is registering an aggregate of
The prospectus lists the securities that may be offered from time to time — common shares, preferred shares, debt securities, subscription receipts, warrants and units — and states specific terms will be provided in prospectus supplements.
enGene Holdings Inc. filed Amendment No. 1 to its annual report to add the previously omitted Part III disclosures on directors, governance, executive compensation, ownership and auditor matters, and to update certain exhibits.
The amendment does not change prior financial statements and is meant to be read together with the original annual report. It details a nine‑member, majority‑independent, staggered board, outlines the roles of key committees, and describes the company’s code of conduct and insider trading policy. It also provides 2025 compensation data for the CEO, CFO and Chief Medical Officer and summarizes the 2023 Incentive Equity Plan, including stock option practices, severance terms and change‑of‑control treatment for equity awards.
enGene Holdings Inc. (ENGN) received an updated large-holder disclosure as Venrock-affiliated funds and related individuals reported beneficial ownership of 4,771,414 Common Shares, representing 7.1% of the company as of December 31, 2025.
The ownership is spread across Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., and related management entities, with Nimish Shah and Bong Y. Koh as voting members. The percentage is based on 66,984,661 Common Shares outstanding as of December 17, 2025. The group certifies the shares were not acquired to change or influence control of enGene.
Cormorant Asset Management, LP and Bihua Chen have disclosed a significant passive stake in enGene Holdings Inc. common shares. They report beneficial ownership of 4,000,000 common shares, representing 5.97% of the class, held through certain Cormorant funds.
The percentage is calculated using 66,984,661 common shares outstanding as of December 17, 2025, as stated in enGene’s Form 10-K. All 4,000,000 shares are reported with shared voting and shared dispositive power, with no sole voting or dispositive power. The holding is certified as being in the ordinary course of business and not for the purpose of changing or influencing control of enGene.
Kynam Capital Management and related reporting persons disclose a 2.23% beneficial stake in enGene Holdings Inc. common shares on an amended Schedule 13G. They report beneficial ownership of 1,492,898 common shares, with shared voting and dispositive power and no sole voting or dispositive authority.
The filing names Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang as reporting persons and certifies the shares are held in the ordinary course of business, not for the purpose of changing or influencing control of enGene.
enGene Holdings Inc. reported a new equity award to its Chief Scientific Officer, Anthony Tzeyew Cheung. On January 30, 2026, he received a stock option to buy 195,000 common shares at an exercise price of $9.53 per share.
The option vests monthly in substantially equal amounts over 48 months, conditioned on his continued service. After this grant, he beneficially owns 195,000 derivative securities directly, aligning his compensation more closely with the company’s future share performance.
enGene Holdings Inc. reported a new stock option grant to its Chief Legal Officer and Corporate Secretary, Lee G. Giguere. On 01/30/2026, Giguere received a stock option for 195,000 common shares with an exercise price of $9.53, reported as held directly.
The option was granted at no cost and is structured to vest monthly in substantially equal amounts over 48 months, subject to Giguere’s continued service with the company. After this grant, Giguere beneficially owned 195,000 stock options tied to enGene common shares.